$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Tuberculosis (TB) remains a global epidemic. In 2023, an estimated 10.8 million people developed TB, and there were approximately 1.25 million deaths, making it once again the leading cause of death from a single infectious agent, according to the WHO Global Tuberculosis Report1. The incidence has risen over the last decade as worldwide travel has become more common and the number of immunocompromised patients has climbed.
After lung and lymph nodes, osteoarticular TB is the third most common site of TB and accounts for 10% to 20% of all extrapulmonary TB cases2,3. Hand involvement is considerably infrequent, occurring in 10% of individuals with osteoarticular TB4. Following involvement of the lymphatic, genitourinary, bone and joint, miliary, and meningeal systems, abdominal TB is the sixth most frequent location of extrapulmonary TB5. Isolated TB infection of the hand or abdomen is uncommon; co-infection of both the hand and abdomen is even more scarce. Hand TB is insidious, often mimicking benign tumors (e.g., enchondroma) or chronic infections due to its nonspecific presentation: localized swelling, pain, and lytic bone lesion, the radiographs showing a well-defined, lytic, and slightly expansile lesion in the phalanx, features that commonly mimic benign cartilaginous tumors such as enchondroma. Diagnostic delays are common, as cultures frequently yield negative results in paucibacillary lesions. Similarly, peritoneal TB is diagnostically elusive, with ascitic fluid analysis and imaging (e.g., CT) serving as cornerstones. Elevated CA-125 and positive interferon-gamma release assays (IGRAs) may heighten suspicion, yet histopathological confirmation by biopsy remains critical6.
To our knowledge, the rare report presents a case of concurrent tuberculous osteomyelitis of the hand and peritoneal TB in a 19-year-old male with no overt risk factors6. Initially misdiagnosed as an enchondroma due to lytic bone changes, the patient later developed acute peritonitis, prompting a re-evaluation. The case underscores the protean manifestations of TB, emphasizing the role of advanced diagnostics (e.g., fluorescence in situ hybridization [FISH]) and multidisciplinary
Case presentation:
A 19-year-old male college student presented with an 8-month history of progressive swelling and pain of the right little finger and 10 days of abdominal discomfort. He denied trauma, animal bites, or prior TB contact but reported a family history of TB in his grandfather. At a local hospital, finger radiographs showed a lytic expansile lesion, leading to a presumptive diagnosis of enchondroma and planned excision. Preoperative chest CT revealed a small pleural effusion, and abdominal CT showed ascites with diffuse peritoneal thickening. Ascitic analysis confirmed exudative fluid (Rivalta test positive), with elevated CA-125 (85.7 U/mL) and a positive IGRA (Table 1), suggesting tuberculous peritonitis. The finger operation was cancelled, and he was referred to our hospital.
There were no complaints of systemic infection signs, such as cough, weight loss, fever, or night sweats. Physical examination demonstrated a painful, tender little finger with diffuse swelling centered at the lateral side of the proximal phalanx. Nodular lesions and chronic inflammatory changes could be seen on the surface of the skin (Figure 1A). There was no erythema or abnormal warmth. Except for mild tenderness in the right lower quadrant, there were no other positive abdominal signs.
Diagnosis, Assessment, and Plan:
The laboratory evaluation revealed a slight rise in CA-125. Blood count and erythrocyte sedimentation rate were within normal limits. Anteroposterior and lateral radiographs of the little finger were taken (Figure 2A,B). The only indication of a current or previous infection on the chest CT scan was a small pleural effusion. Abdomen CT showed diffuse thickening of the peritoneum and omentum, peritonitis, and a small amount of ascites (Figure 2C).
Initial treatment regimens were amikacin, levofloxacin, and azithromycin. A consultation was sent to us for the treatment of a hand lesion. The bone changes of the little finger were initially diagnosed as enchondroma due to imaging findings of a lytic and slightly expansile lesion. The initial operation involved the patient having a deep tumor removed and the nodule being incised and drained. The subcutaneous region had a significant quantity of necrotic and myxomatous granulation tissue excised, with considerable bone involvement (Figure 1B,C). A hole could be seen in the bone clearly after debridement. Inflammatory tissue in the bone could be seen through the hole. The involved tissue was mostly colorless. All the removed tissue was sent for histopathology as well as for regular microbial culture and acid-fast bacilli culture. Surgical debridement was undertaken not only to relieve local symptoms and remove necrotic tissue, but also to obtain adequate specimens for histopathology and culture, and to reduce bacterial load. A vacuum-sealing drainage device was used for adequate drainage. After 7 days from the first surgery, bone grafting to fill the hole of bone and local flap transfer were performed to cover the wound.
Regular microbial culture and acid-fast bacilli culture were negative. Histopathology examination of the lesions showed granulomatous inflammation with necrosis (Figure 3), and TB infection was excluded. Immunohistochemical results showed positive acid-fast staining (Figure 4A), and fluorescence in situ hybridization (FISH) results showed positive for Mycobacterium tuberculosis (Figure 4B). Notably, fluorescence in situ hybridization (FISH) offered a critical diagnostic advantage in this paucibacillary lesion: unlike conventional staining and culture that often fail due to the very low bacterial load, FISH enabled direct visualization of M. tuberculosis within tissue sections, thereby providing timely confirmation when other methods were inconclusive
Based on the FISH results, the treatment regimen was adjusted to an HRZE course (isoniazid, rifampicin, pyrazinamide, and ethambutol) for 12 months, with amikacin and levofloxacin administered for an initial 2-week course. The patient was advised to follow up with an outpatient for further care. Home-based antituberculosis chemotherapy lasted 12 months.